Advertisement

Patterns of LC3A Autophagy Protein Expression in Keratoacanthomas

  • Efthimios SivridisEmail author
  • Ioannis M. Koukourakis
  • Stella Arelaki
  • Kostantina Balaska
  • Antonios Karpouzis
  • Alexandra Giatromanolaki
Original Paper

Abstract

To investigate the expression patterns of autophagy marker light chain protein 3 (LC3A) in keratoacanthoma (KA). KAs are generally regarded as benign but malignant behavior, including rare metastases, may occur. 85 KAs were assessed for the LC3A autophagic protein by immunohistochemistry. Diffuse cytoplasmic staining and a “stone-like structure” (SLS) characterized positive expression. Thirty-four out of 85 KAs (40%) had diffuse cytoplasmic LC3A immunostaining (percentage of positive cells ranging from 5 to 60%). In contrast, only 4 of the 85 KAs (4.7%) expressed SLSs. Only one SLS was detected per histologic section of each tumor. The p53 oncoprotein was encountered in all cases with expression ranging from 1 to 90% of cells (median 30%). The Ki-67 index was expressed in 63 cases (74% of cases; range 1–50% of cells; median value 5%). Neither of these two parameters nor diffuse cytoplasmic LC3A staining was significantly correlated with SLS expression or lack thereof. Expression of SLSs, a hallmark of malignancy, was found in 4.7% of KAs. Further study is necessary to determine whether this fraction represents the exceptional cases that harbor latent malignant potential.

Keywords

Keratoacanthoma Autophagy LC3A Stone-like structures P53 Ki67 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Savage JA, Maize JC, Sr. Keratoacanthoma clinical behavior: a systematic review. Am J Dermatopathol. 2014;36:422–9.CrossRefGoogle Scholar
  2. 2.
    Oellers P, Karp CL, Shah RR, et al. Conjunctival keratoacanthoma. Br J Ophthalmol. 2014;98:275–6.CrossRefGoogle Scholar
  3. 3.
    Ko CJ. Keratoacanthoma: facts and controversies. Clin Dermatol. 2010;28:254–61.CrossRefGoogle Scholar
  4. 4.
    Piscioli F, Boi S, Zumiani G, et al. A gigantic, metastasizing keratoacanthoma. Report of a case and discussion on classification. Am J Dermatopathol. 1984;6:123–9.CrossRefGoogle Scholar
  5. 5.
    Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332–42.CrossRefGoogle Scholar
  6. 6.
    Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol. 2009;26:150–63.CrossRefGoogle Scholar
  7. 7.
    Weedon D. Weedon’s skin pathology. Keratoacanthoma centrifugum marginatum. Edinburg: Churchill Livingstone Elsevier; 2010. p. 702–8.Google Scholar
  8. 8.
    Godbolt AM, Sullivan JJ, Weedon D. Keratoacanthoma with perineural invasion: a report of 40 cases. Australas J Dermatol. 2001;42:168–71.CrossRefGoogle Scholar
  9. 9.
    Weedon D, Malo J, Brooks D, et al. Keratoacanthoma: is it really a variant of squamous cell carcinoma? ANZ J Surg. 2010;80:129–30.CrossRefGoogle Scholar
  10. 10.
    Ra SH, Su A, Li X, et al. Keratoacanthoma and squamous cell carcinoma are distinct from a molecular perspective. Mod Pathol. 2015;28:799–806.CrossRefGoogle Scholar
  11. 11.
    Gleich T, Chiticariu E, Huber M, et al. Keratoacanthoma: a distinct entity? Exp Dermatol. 2016;25:85–91.CrossRefGoogle Scholar
  12. 12.
    Ogita A, Ansai SI, Misago N, et al. Histopathological diagnosis of epithelial crateriform tumors: Keratoacanthoma and other epithelial crateriform tumors. J Dermatol. 2016;43:1321–31.CrossRefGoogle Scholar
  13. 13.
    Manstein CH, Frauenhoffer CJ, Besden JE. Keratoacanthoma: is it a real entity? Ann Plast Surg. 1998;40:469–72.CrossRefGoogle Scholar
  14. 14.
    Sarma D. Keratoacanthoma should be reported as “well differentiated squamous cell carcinoma, Keratoacanthoma Type”: a dermatopathologist’s view. Internet J Dematol. 2006;5:1.Google Scholar
  15. 15.
    Goldenberg G, Patel S, Patel MJ, et al. Eruptive squamous cell carcinomas, keratoacanthoma type, arising in a multicolor tattoo. J Cutan Pathol. 2008;35:62–4.CrossRefGoogle Scholar
  16. 16.
    Sivridis E, Koukourakis MI, Zois CE, Ledaki I, Ferguson DJ, Harris AL, Gatter KC, Giatromanolaki A. LC3A-positive light microscopy detected patterns of autophagy and prognosis in operable breast carcinomas. Am J Pathol. 2010;176:2477–89.CrossRefGoogle Scholar
  17. 17.
    Giatromanolaki A, Sivridis E, Mendrinos S, et al. Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urol Oncol. 2014;32:39.e11-8.CrossRefGoogle Scholar
  18. 18.
    Giatromanolaki A, Koukourakis MI, Harris AL, et al. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. J Clin Pathol. 2010;63:867–72.CrossRefGoogle Scholar
  19. 19.
    Sivridis E, Giatromanolaki A, Karpathiou G, et al. LC3A-positive “stone-like” structures in cutaneous squamous cell carcinomas. Am J Dermatopathol. 2011;33:285–90.CrossRefGoogle Scholar
  20. 20.
    Karpathiou G, Sivridis E, Koukourakis MI, et al. Light-chain 3A autophagic activity and prognostic significance in non-small cell lung carcinomas. Chest. 2011;140:127–34.CrossRefGoogle Scholar
  21. 21.
    Sivridis E, Koukourakis MI, Mendrinos SE, et al. Patterns of autophagy in urothelial cell carcinomas—the significance of “stone-like” structures (SLS) in transurethral resection biopsies. Urol Oncol. 2013;31:1254–60.CrossRefGoogle Scholar
  22. 22.
    Giatromanolaki A, Sivridis E, Mitrakas A, et al. Autophagy and lysosomal related protein expression patterns in human glioblastoma. Cancer Biol Ther. 2014;15:1468–78.CrossRefGoogle Scholar
  23. 23.
    Sivridis E, Giatromanolaki A, Liberis V. Autophagy in endometrial carcinomas and prognostic relevance of ‘stone-like’ structures (SLS) What is destined for the atypical endometrial hyperplasia? Autophagy. 2011;7:74–82.CrossRefGoogle Scholar
  24. 24.
    Giatromanolaki A, Koukourakis M, Koutsopoulos, et al. Autophagy and hypoxia in colonic adenomas related to aggressive features. Colorectal Dis. 2013;15:e223-30.CrossRefGoogle Scholar
  25. 25.
    Liao W, Sun L, Wang C, Huang H, Liu J, Liao W, Shi M. LC3A-positive “stone-like” structures predict an adverse prognosis of gastric cancer. Anat Rec (Hoboken). 2014;297:653–62.CrossRefGoogle Scholar
  26. 26.
    Xi SY, Lu JB, Chen JW, et al. The “stone-like” pattern of LC3A expression and its clinicopathologic significance in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013;431:760–6.CrossRefGoogle Scholar
  27. 27.
    Spowart JE, Townsend KN, Huwait H, et al. The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J Pathol. 2012;228:437–47.CrossRefGoogle Scholar
  28. 28.
    Sivridis E, Giatromanolaki A, Zois C, et al. The “stone-like” pattern of autophagy in human epithelial tumors and tumor-like lesions. An approach to the clinical outcome. Autophagy. 2010;6:122–5.CrossRefGoogle Scholar
  29. 29.
    Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell Res. 2014;24:24–41.CrossRefGoogle Scholar
  30. 30.
    Mizushima N. Autophagy: process and function. Genes Dev. 2007;21:2861–73.CrossRefGoogle Scholar
  31. 31.
    Klionsky DJ, Baehrecke EH, Brumell JH, et al. A comprehensive glossary of autophagy-related molecules and processes (2nd ed.). Autophagy 2011;7:1273–94.CrossRefGoogle Scholar
  32. 32.
    Musiwaro P, Smith M, Manifava M, et al. Characteristics and requirements of basal autophagy in HEK 293 cells. Autophagy. 2013;9:1407–17.CrossRefGoogle Scholar
  33. 33.
    Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11:1566–72.CrossRefGoogle Scholar
  34. 34.
    Joshi S, Schjølberg AR, Ekstrøm PO, et al. Tp53/p53 status in keratoacanthomas. J Cutan Pathol. 2016;43:571–8.CrossRefGoogle Scholar
  35. 35.
    Watanabe IC, Magalhães RF, de Moraes AM, et al. Keratoacanthoma and keratoacanthoma-like squamous cell carcinoma: similar morphology but different pathogenesis. Medicine (Baltimore). 2015;94:e934.CrossRefGoogle Scholar
  36. 36.
    Martinet W, Roth L, De Meyer GRY, Standard immunohistochemical assays to assess autophagy in mammalian tissue. Cells. 2017;6(3):17.CrossRefGoogle Scholar
  37. 37.
    Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.CrossRefGoogle Scholar
  38. 38.
    Amorim E. Solitary fibrous tumor of the pleura: 3 case reports. Rev Assoc Med Bras. 2015;61:207–8.CrossRefGoogle Scholar
  39. 39.
    Thway K, Ng W, Noujaim J, et al. The current status of solitary fibrous tumor: diagnostic features, variants, and genetics. Int J Surg Pathol. 2016;24:281–92.CrossRefGoogle Scholar
  40. 40.
    Strickland KC, Nucci MR, Esselen KM, et al. Solitary fibrous tumor of the uterus presenting with lung metastases: a case report. Int J Gynecol Pathol. 2016;35:25–9.CrossRefGoogle Scholar
  41. 41.
    Akahane K, Kato K, Ogiso S, Sakaguchi K, et al. Malignant granular cell tumor of the breast: case report and literature review. Breast Cancer. 2015;22:317–23.CrossRefGoogle Scholar
  42. 42.
    Martignoni G, Pea M, Zampini C, et al. PEComas of the kidney and of the genitourinary tract. Semin Diagn Pathol. 2015;32:140–59.CrossRefGoogle Scholar
  43. 43.
    Doyle LA, Hornick JL, Fletcher CD. PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2013;37:1769–82.CrossRefGoogle Scholar
  44. 44.
    Do BA, Varshney R, Zawawi F, et al. Inflammatory myofibroblastic tumor of the larynx-a case report. J Voice. 2014;28:258–61.CrossRefGoogle Scholar
  45. 45.
    Lai LM, McCarville MB, Kirby P, et al. Shedding light on inflammatory pseudotumor in children: spotlight on inflammatory myofibroblastic tumor. Pediatr Radiol. 2015;45:1738–52.CrossRefGoogle Scholar
  46. 46.
    Strieth S, Hartschuh W, Pilz L, et al. Carcinoma-like vascular density in atypic keratoacanthoma suggests malignant progression. Br J Cancer. 2002;87:1301–7.CrossRefGoogle Scholar
  47. 47.
    Chow TK, Chacko E, Cleary C, et al. Keratoacanthoma of the lower eyelid. Eye (Lond). 2005;19:689–90.CrossRefGoogle Scholar
  48. 48.
    Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2006;126:2308–15.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Departments of PathologyDemocritus University of Thrace Medical School and University General Hospital of AlexandroupolisAlexandroupolisGreece
  2. 2.Departments of DermatologyDemocritus University of Thrace Medical School and University General Hospital of AlexandroupolisAlexandroupolisGreece

Personalised recommendations